Special Issue "Role of Bacterial Infection in Cancer"
Deadline for manuscript submissions: closed (30 November 2019).
Interests: bacterial infection; colonic crypt hyperplasia; Cancer Stem Cells; mechanisms of chemoprevention by dietary factors and its novel derivatives
Interests: public health; primary care; prevention; health promotion; cancer control; colorectal cancer screening and prevention; the microbiome; Community based research; health disparities research
Microbes are causally implicated in slightly over 20% of all human cancers. Viruses, bacteria and parasites are among the most important pathogens associated with carcinogenesis. The idea that bacterial infection can cause cancer has recently been accepted following the discovery of H. pylori’s role in gastric carcinogenesis. Chronic inflammation, triggered by bacteria, can promote DNA damage and when combined with signals for cell proliferation and elevated angiogenesis, create an environment conducive for cellular transformation and tumorigenesis. Whether causative or not, bacterial presence in the tumor microenvironment has been repeatedly detected in many cancer types. Yet, there is little data regarding the number and identity of the bacteria that reside in the tumor microenvironment. The global spread of antibiotic-resistant pathogens have the potential to increase the mortality of cancer patients. It is plausible that chemotherapy contributes towards the emergence of antibiotic-resistant bacteria within the gut and, in combination with antibiotics, drives pathogen overgrowth thereby disrupting commensal gut microbiology and promoting infection-induced mutagenesis. Opportunities therefore exist for exploiting tumor-specific bacterial growth for cancer treatment and therapies that restore the gut microbiota following chemotherapy or antibiotics could mitigate treatment failure. It is therefore imperative to focus on understanding the mechanistic basis of malignant transformation initiated by pathogens, an area that promises exciting prophylactic, diagnostic, and therapeutic applications.
This Special Issue will provide an open access opportunity to publish research work and review articles related to the role of microbiota in general and bacterial constituents of the microbiome in particular, in cellular transformation and progression of cancer and how microbial products influence the outcome of chemo- and immunotherapies, respectively.
Prof. Dr. Shahid Umar
Prof. Dr. K. Allen Greiner
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cellular transformation